PubMed:30057015 JSONTXT

{"project":"yaoziqian_800_3","denotations":[{"id":"T1","span":{"begin":15,"end":24},"obj":"CI"},{"id":"T10","span":{"begin":1933,"end":1942},"obj":"CI"},{"id":"T11","span":{"begin":1947,"end":1955},"obj":"CI"},{"id":"T15","span":{"begin":111,"end":126},"obj":"DP"},{"id":"T16","span":{"begin":141,"end":163},"obj":"DP"},{"id":"T17","span":{"begin":425,"end":447},"obj":"DP"},{"id":"T18","span":{"begin":404,"end":412},"obj":"DP"},{"id":"T20","span":{"begin":543,"end":551},"obj":"DP"},{"id":"T21","span":{"begin":1978,"end":1986},"obj":"DP"},{"id":"T22","span":{"begin":1999,"end":2002},"obj":"DP"},{"id":"T23","span":{"begin":449,"end":452},"obj":"DP"},{"id":"T24","span":{"begin":564,"end":567},"obj":"DP"},{"id":"T4","span":{"begin":305,"end":314},"obj":"CI"},{"id":"T5","span":{"begin":319,"end":327},"obj":"CI"},{"id":"T8","span":{"begin":739,"end":748},"obj":"CI"},{"id":"T9","span":{"begin":753,"end":761},"obj":"CI"},{"id":"T25","span":{"begin":677,"end":686},"obj":"CI"},{"id":"T26","span":{"begin":991,"end":1000},"obj":"CI"},{"id":"T27","span":{"begin":1325,"end":1332},"obj":"CI"},{"id":"T28","span":{"begin":193,"end":200},"obj":"CI"},{"id":"T29","span":{"begin":495,"end":502},"obj":"CI"},{"id":"T30","span":{"begin":699,"end":706},"obj":"CI"},{"id":"T31","span":{"begin":972,"end":979},"obj":"CI"},{"id":"T32","span":{"begin":1911,"end":1918},"obj":"CI"},{"id":"T33","span":{"begin":29,"end":37},"obj":"CI"},{"id":"T34","span":{"begin":647,"end":655},"obj":"CI"},{"id":"T35","span":{"begin":1006,"end":1014},"obj":"CI"}],"text":"The effects of probiotic and selenium co-supplementation on mental health parameters and metabolic profiles in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial.\nBACKGROUND AND AIMS: The objective of this investigation was to assess the effects of probiotic and selenium co-supplementation on indicators of mental health and metabolic profiles in diabetic people with coronary heart disease (CHD).\nMETHODS: This randomized, double-blind, placebo-controlled trial was conducted among 54 diabetic people with CHD. Patients were randomly allocated into two groups to receive either 200 μg/day selenium plus 8 × 109 CFU/day probiotic (n = 27) or placebo (n = 27) for 12 weeks.\nRESULTS: Probiotic and selenium co-supplementation significantly decreased Beck Depression Inventory index (β -1.46; 95% CI, -2.61, -0.31; P = 0.01) and Beck Anxiety Inventory index (β -1.23; 95% CI, -2.33, -0.12; P = 0.02) compared with the placebo. Consuming probiotic plus selenium lowered fasting plasma glucose (β -10.80 mg/dL; 95% CI, -17.68, -3.92; P = 0.003), serum insulin levels (β -3.42 μIU/mL; 95% CI, -4.93, -1.90; P \u003c 0.001), insulin resistance (β -0.96; 95% CI, -1.45, -0.47; P \u003c 0.001), and enhanced insulin sensitivity (β 0.01; 95% CI, 0.007, 0.01; P \u003c 0.001) compared with the placebo. Additionally, co-supplementation reduced triglycerides (β -34.45 mg/dL; 95% CI, -56.18, -12.72; P = 0.003), VLDL- (β -6.89 mg/dL; 95% CI, -11.23, -2.54; P = 0.003), total cholesterol (β -18.13 mg/dL; 95% CI, -23.42, -2.83; P = 0.02) and high sensitivity C-reactive protein (β -1043.28 ng/mL; 95% CI, -1929.67, -156.89; P = 0.02), and increased nitric oxide (β 7.86 μmol/L; 95% CI, 5.63, 10.09; P \u003c 0.001), total antioxidant capacity (β 119.30 mmol/L; 95% CI, 63.04, 175.57; P \u003c 0.001) and total glutathione (β 154.16 μmol/L; 95% CI, 82.57, 225.74; P \u003c 0.001) compared with the placebo.\nCONCLUSIONS: Probiotic and selenium co-supplementation to diabetic people with CHD improved indicators of mental health and metabolic profiles. Registered under Clinical Trials.gov Identifier no. http://www.irct.ir: IRCT20170513033941N28."}

{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T1","span":{"begin":15,"end":24},"obj":"CI"},{"id":"T10","span":{"begin":1947,"end":1955},"obj":"CI"},{"id":"T11","span":{"begin":739,"end":748},"obj":"CI"},{"id":"T12","span":{"begin":1933,"end":1942},"obj":"CI"},{"id":"T13","span":{"begin":111,"end":126},"obj":"DP"},{"id":"T14","span":{"begin":449,"end":452},"obj":"DP"},{"id":"T15","span":{"begin":564,"end":567},"obj":"DP"},{"id":"T16","span":{"begin":1999,"end":2002},"obj":"DP"},{"id":"T17","span":{"begin":425,"end":447},"obj":"DP"},{"id":"T18","span":{"begin":141,"end":163},"obj":"DP"},{"id":"T19","span":{"begin":404,"end":412},"obj":"DP"},{"id":"T2","span":{"begin":305,"end":314},"obj":"CI"},{"id":"T21","span":{"begin":543,"end":551},"obj":"DP"},{"id":"T22","span":{"begin":1978,"end":1986},"obj":"DP"},{"id":"T3","span":{"begin":677,"end":686},"obj":"CI"},{"id":"T4","span":{"begin":991,"end":1000},"obj":"CI"},{"id":"T5","span":{"begin":29,"end":37},"obj":"CI"},{"id":"T6","span":{"begin":319,"end":327},"obj":"CI"},{"id":"T7","span":{"begin":647,"end":655},"obj":"CI"},{"id":"T8","span":{"begin":753,"end":761},"obj":"CI"},{"id":"T9","span":{"begin":1006,"end":1014},"obj":"CI"},{"id":"T23","span":{"begin":1325,"end":1332},"obj":"CI"},{"id":"T24","span":{"begin":495,"end":502},"obj":"CI"},{"id":"T25","span":{"begin":193,"end":200},"obj":"CI"},{"id":"T26","span":{"begin":699,"end":706},"obj":"CI"},{"id":"T27","span":{"begin":972,"end":979},"obj":"CI"},{"id":"T28","span":{"begin":1911,"end":1918},"obj":"CI"}],"text":"The effects of probiotic and selenium co-supplementation on mental health parameters and metabolic profiles in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial.\nBACKGROUND AND AIMS: The objective of this investigation was to assess the effects of probiotic and selenium co-supplementation on indicators of mental health and metabolic profiles in diabetic people with coronary heart disease (CHD).\nMETHODS: This randomized, double-blind, placebo-controlled trial was conducted among 54 diabetic people with CHD. Patients were randomly allocated into two groups to receive either 200 μg/day selenium plus 8 × 109 CFU/day probiotic (n = 27) or placebo (n = 27) for 12 weeks.\nRESULTS: Probiotic and selenium co-supplementation significantly decreased Beck Depression Inventory index (β -1.46; 95% CI, -2.61, -0.31; P = 0.01) and Beck Anxiety Inventory index (β -1.23; 95% CI, -2.33, -0.12; P = 0.02) compared with the placebo. Consuming probiotic plus selenium lowered fasting plasma glucose (β -10.80 mg/dL; 95% CI, -17.68, -3.92; P = 0.003), serum insulin levels (β -3.42 μIU/mL; 95% CI, -4.93, -1.90; P \u003c 0.001), insulin resistance (β -0.96; 95% CI, -1.45, -0.47; P \u003c 0.001), and enhanced insulin sensitivity (β 0.01; 95% CI, 0.007, 0.01; P \u003c 0.001) compared with the placebo. Additionally, co-supplementation reduced triglycerides (β -34.45 mg/dL; 95% CI, -56.18, -12.72; P = 0.003), VLDL- (β -6.89 mg/dL; 95% CI, -11.23, -2.54; P = 0.003), total cholesterol (β -18.13 mg/dL; 95% CI, -23.42, -2.83; P = 0.02) and high sensitivity C-reactive protein (β -1043.28 ng/mL; 95% CI, -1929.67, -156.89; P = 0.02), and increased nitric oxide (β 7.86 μmol/L; 95% CI, 5.63, 10.09; P \u003c 0.001), total antioxidant capacity (β 119.30 mmol/L; 95% CI, 63.04, 175.57; P \u003c 0.001) and total glutathione (β 154.16 μmol/L; 95% CI, 82.57, 225.74; P \u003c 0.001) compared with the placebo.\nCONCLUSIONS: Probiotic and selenium co-supplementation to diabetic people with CHD improved indicators of mental health and metabolic profiles. Registered under Clinical Trials.gov Identifier no. http://www.irct.ir: IRCT20170513033941N28."}